Vlad Coric

October 17, 2026

Royalty Pharma Declares Q4 2026 Dividend. Royalty Pharma announced its fourth-quarter 2026 dividend, a routine move that supports its status as a consistent income provider with a yield near 3%. Recent commentary also highlights the company's valuation metrics, noting that its multiples may offer an attractive risk-reward balance for some market participants. The stock currently trades within its 52-week range, with analysts maintaining a consensus target price above current levels.

October 10, 2026

Veradermics Momentum Builds, But H2 2026 Readouts Caution. Veradermics has seen growing momentum, but analysts caution that upcoming H2 2026 readouts could influence the stock. The company was included among 12 healthcare stocks that moved higher in Thursday’s intraday session. While the news highlights positive sentiment, investors should note the caution about future readouts. The stock remains near its 52‑week low, with a support level at $97.79.

October 13, 2026

Biohaven signs $100M deal with Ono for IgG degraders. Biohaven has entered a strategic licensing agreement with Ono Pharma for its IgG degrader technology in Japan and select Asian regions. The deal includes up to $100 million in near-term payments, with $80 million paid upfront. This move expands the company's presence in Asia and supports its lead candidate, BHV-1300, which is currently in Phase 3 trials for Graves' disease.